Aphios Corporation
Aphios Home Page
Company
Infectious Diseases
Oncology and CNS Disorders
Nutraceuticals
Product Pipeline
Purchase Products
Technology Platforms
Technology Platforms
Patents

Press Releases

Contact Aphios

 

 

SuperFluids™ CFI

Bacteriophage VirusSuperFluids™ CFI technology works by first permeating and inflating the pathogen particles with a selected SuperFluid™.  SuperFluids™ [SFS] are gases, such as carbon dioxide and nitrous oxide which, when compressed exhibit enhanced thermodynamic properties of penetration, solvation and expansion. The overfilled particles are then decompressed, the dense-phase fluid rapidly changes into a gaseous state rupturing the pathogen particles at their weakest points – very much like the embolic disruption of the ear drums of a scuba diver who surfaces too rapidly – and becomes inactive. The now gaseous SuperFluids™ leave the protein-rich substrate with no toxic residuals to be removed.

SFS-CFI thus has the ability to physically disrupt and inactivate pathogen particles, explaining its ability to inactivate nonenveloped viruses such as polio, and a variety of other tough microorganisms such as yeast and other Gram-positive microorganisms. SFS-CFI also inactivates enveloped viruses, such as HIV and influenza, by a partial phospholipid solubilization/liberation mechanism. SFS-CFI of enveloped viruses such as MuLV, VSV, TGE, BVD, Sindbis and HIV, and non-enveloped viruses such as Hepatitis A, Polio, Adeno, Reo, EMC and Parvovirus B19 has been demonstrated. In summary, SFS-CFI:Inactivation Levels

  • Disrupts and inactivates bacterial pathogens
  • Inactivates both enveloped & non-enveloped viruses
  • Employs no chemicals and non-toxic solvents
  • Rapid technique (> 6 logs in less than 20 seconds for some viruses)
  • Low temperatures (10 to 50°C)
  • Competitive processing costs
  • Applicable to liquids and solids
  • Scalable and amenable to continuous operation

SFS-CFI can inactivate a broad range of enveloped and non-enveloped viruses, as much as 6 logs (1 million particles per milliliter) in less than 20 seconds. Increasing the number of stages, like a distillation column, increases inactivation levels. Volumetric throughput is increased by increasing cross-sectional area.

This technology does not damage proteins and enzymes since it is purely physical and does not involve the use of chemicals, heat or irradiation. A key feature of this technology is that proteins and enzymes are negligibly impacted and remain biologically active. Based on purely physical principles, SFS-CFI does not rely on potentially toxic organic solvents, DNA/RNA modifying chemicals, denaturing heat or irradiation techniques.

SFS-CFI is a closed system, fluid-liquid/solid contacting technique that is readily scalable and amenable to batch or continuous flow operations.

 

Home l Company | Infectious Diseases | Oncology | Nutraceuticals | Product Pipeline | Purchase Products | Technology Platforms | Equipment |Patents | Press Releases | Contact Aphios

©1999- 2007 Aphios® Corporation
All rights reserved